Universitätsspital Zürich, Zurich, Switzerland - 25 Jul `24Ruxolitinib cream for nonsegmental vitiligo

Ruxolitinib cream for nonsegmental vitiligo

Official title: Topical Ruxolitinib for the Treatment of Immune-related Vitiligo-like Depigmentation: A Prospective, Multicentre Study of a Topical JAK-inhibitor

Status: Closed to new participants

Description:

University of Zurich plans to enroll about 34 participants. Ruxolitinib cream blocks JAK1 and JAK2 signals that help sustain the immune attack on pigment-producing cells. It is intended to calm inflammation and help affected skin regain color. Ruxolitinib cream is sold as Opzelura and is already approved in the United States for nonsegmental vitiligo in people age 12 and older and for atopic dermatitis. The study is testing a particular population or treatment approach. Possible effects include application-site acne, itching or redness, headache, and infections. People age 18 and older may qualify. The study is underway but is no longer accepting new participants.

Start date: July 25, 2024

Completion date: August 31, 2026

Organizer: University of Zurich

Contact: See contacts and locations in the ClinicalTrials.gov record

Link: https://clinicaltrials.gov/study/NCT07725432

Clinical Trial Alerts

Sign up and be the first to know about updates on this trial.

This request will be sent with the trial reference Ruxolitinib cream for nonsegmental vitiligo . By submitting you agree to our Privacy Policy.

FAQOther Questions